ACET - Adicet Bio, Inc.

0.5858
-0.028   -4.848%

Share volume: 128,788
Last Updated: 04-25-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$0.61
-0.03
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
48%
Profitability 40%
Dept financing 29%
Liquidity 50%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.59%
1 Month
-29.44%
3 Months
-34.48%
6 Months
-59.03%
1 Year
-63.16%
2 Year
-89.97%
Key data
Stock price
$0.59
P/E Ratio 
N/A
DAY RANGE
$0.58 - $0.62
EPS 
-$2.18
52 WEEK RANGE
$0.45 - $1.86
52 WEEK CHANGE
-$63.16
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
82.401 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$184,028
AVERAGE 30 VOLUME 
$529,699
Company detail
CEO: Chen Schor
Region: US
Website: adicetbio.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.

Recent news
loading